H.I.G. Capital News
-
ZUG, SWITZERLAND – January 21, 2021 – Arvelle Therapeutics, an emerging biopharmaceutical company focused on bringing innovative treatments to patients suffering from central nervous system (CNS) disorders, today announced that the Committee for Medicinal Products for Human Use…
-
MARLBOROUGH, MA – January 12, 2021 - CardioFocus, Inc., a medical device company dedicated to advancing ablation treatment for atrial fibrillation (AFib), today announced that Chief Executive Officer & President Burke T. Barrett will present at the 23rd Annual ICR Conference,…
-
MARLBOROUGH, MA – January 11, 2021 – CardioFocus, Inc., a medical device company dedicated to advancing ablation treatment for atrial fibrillation (AFib), announced today that it has expanded its existing French distribution partnership agreement with MicroPort CRM in France to…
-
ROME – January 4, 2021 – Angelini Pharma, an international pharmaceutical company which is a part of the private ItalianAngelini Group – and Arvelle Therapeutics, a Swiss-based biopharmaceutical company focused on bringing innovativetreatments…
-
SAN DIEGO – December 21, 2020 – Neurana Pharmaceuticals, a biotechnology company focused on the treatment of neuromuscular conditions, today announced that the first patient has been enrolled in the Phase 3, RESUME-1, clinical study of tolperisone, a novel, non-opioid, centrally…
-
SAN DIEGO – December 8, 2020 – Neurana Pharmaceuticals, a biotechnology company focused on the treatment of neuromuscularconditions, today announced positive top-line results from the Phase 1 central nervous effects (CNS) clinical study of tolperisone. Thestudy, utilizing a validated…
-
November 24, 2020 - Neurana Pharmaceuticals Announces Publication in the Journal of Pain Research
SAN DIEGO – November 23, 2020 - Neurana Pharmaceuticals, a biotechnology company focused on the treatment of neuromuscular conditions, today announced the publication of results from the dose-ranging Phase 2 STAR Study of tolperisone in patients with acute and painful muscle spasms…
-
BRIDGEWATER, NJ - October 22, 2020 – Nevakar Inc., a biopharmaceutical company developing multiple assets in the ophthalmic and injectable areas, announced today it received approval from the U.S. Food and Drug Administration (FDA) to market Ephedrine Sulfate Injection in a ready-…
-
July 8, 2020 - H.I.G. Capital Acquires Project Informatica
MILAN – July 8, 2020 – H.I.G. Europe (“H.I.G.”), the European affiliate of H.I.G. Capital, a leading global private equity investment firm with more than €34 billion of equity capital under management, announced today the acquisition by an affiliate of a controlling stake…
-
ZUG, SWITZERLAND – May 21, 2020 - Arvelle Therapeutics, an emerging biopharmaceutical company focused on bringing innovative treatments to patients suffering from CNS disorders, today announced the publication of a key trial (013 Study) in Neurology, the official journal of the American…
-
May 13, 2020 - Leiters Awarded a Group Purchasing Agreement by Comprehensive Pharmacy Services
DENVER – May 13, 2020 - Leiters, announced today that it has entered into a strategic arrangement with the newly reorganized group purchasing organization affiliate of Comprehensive Pharmacy Services, LLC (CPS), Comprehensive Purchasing Alliance, LLC (CPA), to be the leading…
-
ZUG, SWITZERLAND – May 12, 2020 - Arvelle Therapeutics, an emerging biopharmaceutical company focused on bringing innovative treatments to patients suffering from CNS disorders, today confirms that SK Life Science, Inc., a subsidiary of SK Biopharmaceuticals Co., Ltd., has now made…
-
SAN DIEGO – May 12, 2020 – Neurana Pharmaceuticals, Inc., a biotechnology pharmaceutical company focused on the treatment of neuromuscular conditions, today announced the publication of a driving study which demonstrates the tolerability and safety of tolperisone in the peer-reviewed…
-
ZUG, SWITZERLAND - March 26, 2020 - Arvelle Therapeutics, an emerging biopharmaceutical company focused on bringing innovative treatments to patients suffering from CNS disorders, today announces that the European Medicines Agency (EMA) has accepted the marketing authorization…
-
NORTHBROOK, Ill. – March 16, 2020 – Clarus Therapeutics, Inc., a commercial men’s health specialty pharmaceutical company, announced today that it has completed a senior debt financing of up to $75M. Morgan Stanley & Co. LLC acted as sole placement agent for the transaction. Clarus…